Atlanta
FDA requires warning labels on GLP-1 drugs about blindness risk
FDA mandates new labels on GLP-1 drugs like Ozempic and Wegovy for potential blindness risk.
The U.S. Food and Drug Administration / Public domain, via Wikimedia Commons
The Food and Drug Administration announced it will require new warning labels on GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, about a potential increased risk of blindness, WSB-TV reported.
These drugs, used for diabetes and weight management, will now carry labels informing patients and healthcare providers of this possible side effect.
The FDA's decision aims to enhance patient safety by ensuring users are aware of all risks associated with these medications.
Atlanta-area patients using these drugs should consult their healthcare providers for guidance and monitoring in light of the new warnings.
Sources
We read public reporting and official data, confirm what we can, and write our own story. See something wrong? Request a correction.
Comments
No comments yet.
Sign in to comment